Efficacy and safety of rituximab in the treatment of refractory pemfigus vulgaris

TEMEL, Asli; Akman-Karakas, AYŞE; Ergun, ERKAN; Ozkesici, BİRGÜL; Ugurlu, NİLAY; NAZLIM, BERNA; Koc, SALİHA; Erat, AYŞEGÜL; Bozkurt, SELEN; Dicle, ÖZLEM; Alpsoy, ERKAN; Yilmaz, ERTAN; UZUN, SONER

doi:10.4274/turkderm.86402

Efficacy and safety of rituximab in the treatment of refractory pemfigus vulgaris

Atıf İçin Kopyala

TEMEL A. B., Akman-Karakas A., Ergun E., Ozkesici B., Ugurlu N., NAZLIM B., ...Daha Fazla

TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, cilt.49, sa.2, ss.117-124, 2015 (ESCI)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 49 Sayı: 2
Basım Tarihi: 2015
Doi Numarası: 10.4274/turkderm.86402
Dergi Adı: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
Sayfa Sayıları: ss.117-124
Anahtar Kelimeler: Rituximab, pemphigus, treatment, PEMPHIGUS, THERAPY, DISORDERS, DEPLETION, DISEASES
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Akdeniz Üniversitesi Adresli: Evet

Özet

Background and Design: Pemphigus vulgaris (PV) is a severe, chronic, potentially life-threatening autoimmune blistering disease that affects the skin and mucous membranes, associated with the loss of cell-cell adhesion and blister formation. Systemic steroids in combination with immunosuppressive agents are the mainstay of therapy in pemphigus. Rituximab, a chimeric monoclonal anti-CD20 antibody, has been tried increasingly for the treatment of PV.